Can Biosimilar Studies Be Conducted Solely In Healthy Volunteers?

Coherus refutes Apotex argument that Neulasta biosimilars must be studied in at least one patient population. Its application could face delay as no advisory committee meeting has been scheduled ahead of its June 9 user fee date.

FDASignBldg21Entrance_1200x675

FDA's review of Coherus BioSciences Inc.'s Neulasta (pegfilgrastim) biosimilar application could shed light on the data sponsors must submit to gain approval of their versions of the granulocyte-colony stimulating factor, particularly whether they must conduct studies in a patient population.

Apotex Inc. submitted a citizen petition to FDA in April asking the agency to require sponsors referencing Amgen...

More from Biosimilars

More from Biosimilars & Generics